It’s All About Impact: Why Orphan Drugs are a Big Deal for Patients and Pipelines
300 million people worldwide are living with a rare disease. The “orphan” drugs created to treat them have been a fast-growing part of the pharma market for years – and their use is often high profile. Every now and then a relative niche of the pharma world hits the mainstream – orphan drugs. It happened […]
